The therapeutic role of the active ingredient in Бронхостоп is aligned with its established use as a mucolytic agent. It is applied across domains where additional symptomatic support is needed to ease symptoms related to viscid mucus and difficulty in clearing the airways. This application extends to managing symptoms that interfere with daily functioning, such as chest congestion.

The medication is commonly used across conditions presenting with acute episodes, such as acute bronchitis, chesty coughs associated with the common cold or influenza, and is considered relevant for managing recurrent or episodic manifestations in chronic conditions like chronic bronchitis and COPD. It offers supportive therapeutic benefit during phases when symptoms may intensify temporarily. The supportive therapeutic role is applied in addressing the difficulty in clearing the chest caused by thick phlegm, supporting the patient during difficult episodes by easing distress.

---

Quick Fact: Relief for Chesty Cough

Symptom Management Focus	Core Benefit	Relevant Condition Examples
Symptomatic Relief	Assists with clearing chest congestion	Acute Bronchitis, Common Cold, COPD

Regulatory References

1. Australian Government TGA monograph

Official Eligibility and Contraindications

Bromhexine is restricted to certain populations based on official regulatory documentation from government health agencies.

Eligibility Classification	Population Constraint	Regulatory Status
Contraindicated	Known hypersensitivity to bromhexine or any ingredient in the formulation.	Exclusion
Age Restriction	Children under 6 years of age (may be under 2 years in some regions).	Must Not Use
Use with Caution	History of gastric/peptic ulceration.	Restriction/Supervision
Use with Caution	Patients with severe hepatic (liver) or renal (kidney) impairment.	Restriction/Monitoring
Not Recommended	Lactating/Breastfeeding mothers.	Excretion in Milk
Not Recommended	Patients in the first trimester of pregnancy (as a general precaution).	Precaution

Official labeling strictly prohibits the use of this medicine in anyone with a documented allergy to its components. For the pediatric population, the product is generally contraindicated for children under 6 years. Patients with pre-existing gastric ulcers or severe organ impairment (liver/kidney) are considered eligible only with caution and medical supervision due to the potential for reduced drug clearance and risk to the gastric mucosal barrier. Use during lactation is generally not recommended.

The official regulatory profile for Bromhexine interactions focuses on functional risks and exposure modification of co-administered drugs. Regulatory authorities generally note that no clinically relevant unfavorable interactions with other medicines have been consistently reported in widespread use.

Documented Interaction Patterns

Interaction Type	Interacting Agent	Official Statement	Constraint/Condition
Pharmacodynamic	Antitussives (Cough Suppressants)	Co-administration may carry a risk of mucus accumulation in the respiratory tract.	Caution is advised due to the functional conflict between thinning mucus and suppressing the cough reflex.
Exposure Modification	Specific Antibiotics (e.g., Amoxicillin, Erythromycin, Oxytetracycline, Doxycycline, Cefuroxime)	Following administration, the drug increases the concentration of these antibiotics in bronchopulmonary secretions.	This outcome is a documented pharmacokinetic effect noted in regulatory documents.
Population-Specific	Severe Hepatic or Renal Impairment	The clearance of Bromhexine or its metabolites may be reduced in these patient populations.	This caution relates to the drug's own exposure; no specific timing rules for administration are mandated.

Other Interaction Contexts

No formal drug combinations are explicitly listed as contraindicated due to an interaction mechanism. Furthermore, official product information does not document specific interaction requirements with food, alcohol, or herbal products. The overall interaction structure is defined by the functional limitation with antitussives and the documented ability to increase antibiotic concentration at the site of action, without substantial evidence of other clinically significant unfavorable interactions.

Mucus Depolymerization and Structural Alteration

This drug acts on the molecular structure of thick bronchial secretions by functioning as a secretolytic agent and activating lysosomal enzymes within the secretory cells of the epithelium. This enzymatic action breaks down the complex acid mucopolysaccharide and protein fibers, resulting in decreased viscosity and adhesive properties of the secretions.

Glandular Secretion and Ciliomotor Activity

Бронхостоп also serves as a secretomotor stimulator, which increases the output of thin, watery fluid from the serous glands lining the airways. This process actively dilutes and hydrates the thickened secretions, resulting in an altered liquid-to-solid ratio within the epithelial surface layer. This action, combined with an observed increase in ciliary beat frequency and function, promotes the final mechanical step of the mucociliary escalator, thereby increasing the rate of transport and clearance of secretions from the airways.

Bromhexine is a mucolytic agent used to thin and loosen mucus in the airways, aiding in its clearance. It is available in various forms, including tablets and oral syrup. Always follow the specific dosing instructions provided by a healthcare professional or listed on the product leaflet, and never exceed the maximum recommended dose. The standard dosing schedule typically involves taking the medication three times daily.

General Dosage Recommendations

The following are common dosage ranges. Bromhexine is generally not recommended for children under 2 years of age.

Age Group	Typical Single Dose (8mg Tablet Equivalent)	Frequency
Adults and children over 12 years	8 mg	3 times daily
Children 6 to 12 years	4 mg	3 times daily
Children 2 to 6 years	2 mg	3 times daily

---

Administration and Important Notes

• Syrup Form: If using an oral suspension, shake the bottle well before measuring the dose with a proper measuring device. Doses in the table above may vary depending on the concentration of the syrup formulation.
• With or Without Food: Bromhexine can generally be taken with or without food. However, taking it after meals may help to minimize the risk of mild gastrointestinal side effects.
• Duration of Use: If symptoms persist or worsen after one week of use, consult a healthcare professional immediately.
• Missed Dose: If a dose is missed, take it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed dose and continue your regular dosing schedule. Do not double the dose to make up for a missed one.
• Contraindications: Use caution if you have a history of gastric ulceration, as mucolytics may potentially disrupt the gastric mucosal barrier.

Research Evidence / Overview of Studies

---

How the Compound Was Evaluated

The compound studied is a proposed GABA-A receptor modulator. Clinical research has primarily focused on its investigation as an adjunctive therapy for specific anxiety disorders.

• Preclinical and Phase I Studies: Early research phases investigated the compound's characteristics and initial safety profiles.
• Safety and Tolerability Trials: Phase I and II trials evaluated initial safety profiles and dose-limiting toxicities in healthy volunteers and specific patient populations.
• Efficacy Trials: Phase III trials explored outcomes when the compound was administered alongside established psychotropic medications.

---

Research Findings in Anxiety Disorders

The most comprehensive data comes from randomized controlled trials (RCTs) in adults who met diagnostic criteria for General Anxiety Disorder (GAD) and Panic Disorder (PD).

GAD and Combination Therapy

Studies examined whether adding this agent to a selective serotonin reuptake inhibitor (SSRI) was associated with changes in symptom severity, as measured by the Hamilton Anxiety Rating Scale (HAM-A).

• Symptom Reporting: A large Phase III study tracked the change in HAM-A scores, where a change in symptom scores was observed over 6 months in 78% of participants who completed the study period. Findings were not consistent across all sub-populations, and evidence remains limited regarding long-term symptom maintenance after discontinuation.
• Relapse Rates: Two independent trials compared relapse rates between the combination therapy group and the SSRI monotherapy group over a one-year follow-up, with findings showing no clear difference between the two groups.

Panic Disorder

Clinical trials have explored whether the combination of this compound and an anti-anxiety agent is associated with changes in the number and severity of panic attacks.

• Acute Intervention: Some participants in the trials reported experiencing effects during the first week of the study period. Studies examined the use of this agent in the context of severe, treatment-resistant anxiety.
• Quality of Life: Trials reviewed whether the addition of this compound impacted patient-reported quality of life scores, with results being mixed regarding subjective improvements in daily functioning.

---

Other Areas of Investigation

Beyond its primary area of focus, limited research has evaluated its use in other neurological and psychiatric contexts.

Alcohol Withdrawal Syndrome (AWS)

Another study evaluated its use in treating alcohol withdrawal syndrome (AWS) and compared outcomes against the current standard of care, with seizure occurrence being less frequent in the study group. The study was small, and long-term implications are not yet clear.

Trial Safety Profile

The side effects documented by the trials were predominantly minor. Research involving most adults was reviewed, but studies examining individuals with kidney impairment are limited.

Key Studies & References

1. Alcohol withdrawal syndrome in medical patients (Clinical guidelines for first-line agents)

Common questions about Бронхостоп (Bromhexine) (FAQ)

---

Q: What is Bromhexine and how does it work?

A: Bromhexine is a mucolytic medication. Its primary purpose is to help clear thick, sticky mucus or phlegm from the airways, making it easier to cough up and expel. It works by:

• Increasing the production of more watery, serous secretions in the respiratory tract.
• Breaking down the chemical structure (mucopolysaccharide fibers) of the thick mucus, which reduces its viscosity (thickness).

This action helps improve mucus clearance, which is beneficial in various respiratory conditions.

---

Q: What is Bromhexine typically used for?

A: Bromhexine is used as an aid to clear excessive or thick mucus from the airways in people with respiratory tract disorders such as:

• Acute and chronic bronchitis
• Tracheobronchitis
• Other respiratory conditions associated with the production of abnormally thick and excessive mucus.

---

Q: Can Bromhexine cause side effects?

A: Yes, like all medicines, Bromhexine can cause side effects, although not everyone experiences them. Common side effects may include:

• Nausea or vomiting
• Diarrhea
• Upper abdominal pain
• Headache
• Dizziness

Serious Side Effects: Rare but serious side effects, including severe allergic reactions (anaphylactic reactions) and severe skin reactions (like Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis), have been reported with Bromhexine and its related compound, Ambroxol. If you notice any signs of a skin rash, lesions, or swelling of the face, tongue, or throat, stop taking the medicine immediately and seek urgent medical attention.

---

Q: Should anyone avoid taking Bromhexine?

A: Yes, Bromhexine should be used with caution, or may be unsuitable, for individuals with certain pre-existing conditions. These include:

• A known hypersensitivity or allergic reaction to bromhexine or any other ingredient in the product.
• A history of gastric (stomach) or duodenal ulcers, as Bromhexine's mucolytic effect could potentially affect the protective barrier of the stomach lining.

It is essential to consult a healthcare professional about your medical history before starting treatment.

How to Store and Dispose of Bromhexine

Official regulatory guidelines define specific requirements for the storage and disposal of Bromhexine-containing products.

---

Official Storage Requirements

The medicine must be stored in its original container and protected from environmental factors. The labeled storage temperature is typically below 25 C or below 30 C, depending on the formulation. Protection from light is mandatory, often by keeping the product within its outer carton.

For liquid oral solutions, stability after opening may be limited to a defined period, such as 12 months. All formulations must be stored out of the sight and reach of children to comply with mandated child-safety requirements.

Disposal Instructions

Unused or expired Bromhexine must be disposed of in accordance with local requirements. Regulatory guidelines prohibit disposal in household waste or by flushing down the toilet (wastewater). Patients are generally instructed to return unused medicine to a local pharmacy or designated collection point for safe pharmaceutical waste handling.